Aliqopa (copanlisib) vs Xalkori (crizotinib)

Aliqopa (copanlisib) is a kinase inhibitor specifically used for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Xalkori (crizotinib), on the other hand, is a small molecule tyrosine kinase inhibitor used primarily for the treatment of certain types of non-small cell lung cancer (NSCLC) that are anaplastic lymphoma kinase (ALK) or ROS1-positive. When deciding between these two medications, it is crucial to consider the specific type of cancer being treated, as Aliqopa is tailored for a particular kind of lymphoma, while Xalkori is indicated for specific genetic mutations in lung cancer.

Difference between Aliqopa and Xalkori

Metric	Aliqopa (copanlisib)	Xalkori (crizotinib)
Generic name	copanlisib	crizotinib
Indications	Relapsed follicular lymphoma	Non-small cell lung cancer, ROS1-positive, and ALK-positive metastatic NSCLC
Mechanism of action	PI3K inhibitor	ALK and ROS1 receptor tyrosine kinase inhibitor
Brand names	Aliqopa	Xalkori
Administrative route	Intravenous	Oral
Side effects	Hyperglycemia, hypertension, neutropenia, etc.	Visual disorders, gastrointestinal effects, edema, etc.
Contraindications	None known specifically; use caution in patients with severe hepatic impairment or with active infections	Hepatic impairment, concurrent use with strong CYP3A inhibitors or inducers
Drug class	Antineoplastic agent, PI3K inhibitor	Antineoplastic agent, tyrosine kinase inhibitor
Manufacturer	Bayer	Pfizer

Efficacy

Efficacy of Aliqopa (Copanlisib) in Treating Lymphoma

Aliqopa (copanlisib) is a kinase inhibitor primarily used in the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. The efficacy of Aliqopa in treating lymphoma was demonstrated in a single-arm, multicenter clinical trial. The trial's primary endpoint was the objective response rate (ORR), which reflects the percentage of patients who achieved either a complete or partial response to the treatment. In this pivotal study, Aliqopa showed an ORR that was deemed clinically significant, leading to its approval by the U.S. Food and Drug Administration (FDA) for this indication.

The duration of response (DOR) in patients treated with Aliqopa was also a key measure in assessing its efficacy. Patients who responded to Aliqopa treatment experienced a median DOR that supported its use as a therapy for relapsed FL. This data suggests that Aliqopa can provide a meaningful clinical benefit in terms of extending the time during which the disease is controlled.

Efficacy of Xalkori (Crizotinib) in Treating Lymphoma

Xalkori (crizotinib) is an anaplastic lymphoma kinase (ALK) inhibitor that is approved for the treatment of non-small cell lung cancer (NSCLC) with ALK or ROS1 genetic alterations. Its efficacy in lymphoma, specifically anaplastic large cell lymphoma (ALCL), has been explored due to the presence of ALK alterations in a subset of ALCL patients. In clinical studies, crizotinib has shown antitumor activity in patients with ALK-positive ALCL, indicating potential efficacy in this type of lymphoma.

However, it is important to note that the use of Xalkori (crizotinib) for lymphoma, including ALCL, is considered off-label, as its FDA approval is currently limited to NSCLC. Off-label use means that the drug has not been approved by the FDA for this specific disease or condition, but may be prescribed by healthcare professionals based on their clinical judgment and the available scientific evidence. The efficacy of Xalkori for lymphoma patients is therefore based on smaller, less definitive studies and requires further clinical trials to fully establish its therapeutic role in this setting.

Regulatory Agency Approvals

Aliqopa

Food and Drug Administration (FDA), USA

Xalkori

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Access Aliqopa or Xalkori today

If Aliqopa or Xalkori are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Aliqopa

Buy Xalkori

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: